Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report Q1 2023

First Quarter (Jan–March 2023) Net sales amounted to TSEK 121,296 (99,305), which is an increase of 22.1 % compared to the same period last year. The gross margin amounted to 56.4 % (59.0). Operating profit before depreciation and amortization (EBITDA) amounted to TSEK 28,459 (28,551), which corresponds to an operating margin before depreciation and amortization of 23.5 % (28.8). Operating profit (EBIT) amounted to TSEK 16,100 (19,856), which corresponds to an operating margin of 13.3 % (20.0). Earnings per share before dilution amounted to SEK 1.16 (1.48). (Comparative

Interim report January–March 2023 – Pricer AB

Q1 2023   · Net sales amounted to SEK 571.4 M (465.9), an increase of 22.6 percent compared to the same period last year. · Of net sales, SEK 14.5 M (10.2) refers to recurring revenue. · Operating profit amounted to SEK –13.9 M (-9.7), which corresponds to an operating margin of –2.4 percent (–2.1). · Order intake was SEK 707 M (551), an increase of 28.3 percent compared to the same period last year. · Order backlog amounted to SEK 613 M (464), of which the majority is expected to be delivered in Q2 and Q3 2023. · Profit for the period was SEK –27.2 M (–9.5). ·

Implantica publishes Annual Report 2022

Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2022. The annual report is now available on the company’s website.“During 2022 RefluxStop™ continued to disrupt the field of anti-reflux treatments with its unique breakthrough approach and excellent patient outcomes. Our main focus remains building and scaling our top commercial priority RefluxStop™ through reimbursement (market access) to become an exceptional growth story,” says Peter Forsell, CEO of Implantica. For further

Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer

LUND, SWEDEN – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company that has launched the world’s first test dedicated to the early detection of pancreatic cancer, today announced it will participate in a webinar titled “Biomarkers and Liquid Biopsy for Early Detection of Pancreatic Cancer” hosted by the National Pancreas Foundation on April 26, 2023, at 7:00 pm ET.   Lara Sucheston-Campbell, Vice President of Clinical and Medical Affairs at Immunovia, and Dr. Rosario Ligresti, Director of the Pancreas Center at Hackensack University Medical Center are scheduled to present as

Interim Management Statement 1 January-31 March 2023

CEO Dr. Martin Edlund: “The need for our tidal energy technology in the global energy transition has never been more clear and accurate than now”Significant events January-March 2023 •In January, the company reached a commercial milestone, having received a first historic sales order of tidal site development services in Asia. Minesto was contracted to support a leading Asian corporation in the offshore energy sector for evaluation of a tidal current site targeting the deployment of Minesto’s Dragon Class tidal energy power plants. • Minesto and the Faroese utility company SEV

Corporate Governance & Engagement Report

Swedbank Robur is the largest fund company in Sweden and an active investor in the market. The new annual report "Corporate Governance & Engagement 2022" presents how Swedbank Robur integrates and works to support and drive sustainability issues, based on its ownership role.The 2022 report states, among other things, that the fund company: •    Voted at 852 general meetings in 35 different markets. •    Evaluated 400 shareholder proposals. •    Voted for 87% of the share capital.•    Participated in 110 nomination committees, more than any other investor in Sweden.  •

Aixia contracts for Proof of Concept to improve plastic product quality using AI

Mölndal                                                                                      2023-04-20 Aixia and a leading company in the plastics industry are jointly conducting a Proof of Concept to improve the quality of plastic products Aixia, formerly known as CGit, has entered into a cooperation agreement with a leading company in the plastics industry and operating globally, to carry out a Proof of Concept (PoC) to automate the quality control of plastic products. Aixia's expertise in AI and smart tools will play a crucial role in the project, which aims to increase efficiency

Nexam Chemical Holding AB (publ) Interim Report 1 January – 31 March 2023

Increased margins and positive cash flow during the quarterFirst quarter at a glance Significant events during the quarter: · Sales decreased by 3% in the quarter while the gross margin increased from 40% to 42%, compared with the corresponding quarter in 2022. · Performance Masterbatch revenue was in line with the corresponding quarter in 2022 and Performance Chemical’s revenue decreased by 6%, compared with the corresponding quarter in 2022. · Received approval for the use of NEXAMITE in bottles and food packaging in Japan · Obtained extended overdraft facility to SEK 20

Asetek A/S (ASTK) – Ex. Preemptive Rights today

Aalborg, 20 April 2023. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Issuer name: Asetek A/S Ex. date: 20 April 2023 Type of corporate action: Preferential rights issue Other information: Please refer to the stock exchange announcement by the Company on 18 April 2023 regarding publication of prospectus and terms of the Rights Issue for additional details. This

Sif orders PEMA plate joining lines for XXXL monopile manufacturing

Sif's production site at Maasvlakte 2-Rotterdam. The company is specialized in foundation design, fabrication, corrosion protection, and logistics services for offshore wind farm developers and EPCI contractors. Photo: Sif Holding N.V. Pemamek Ltd. has won a significant order to supply PEMA production automation solutions to the Dutch offshore wind monopile foundation manufacturer Sif Holding N.V. (Sif). The delivery includes PEMA plate joining lines for XXXL monopile foundation manufacturing and extensive service agreements. Based on innovative and sophisticated production

Kindred expands North American retail footprint by launching in Washington State

Kindred Group continues its North American retail expansion by launching phase one of its partnership with The Swinomish Tribe, Washington State.Kindred Group plc (Kindred) launches a retail operation at the Swinomish Casino & Lodge. This follows the announcement of the six-year agreement with the Swinomish Indian Tribal Community in October 2022. The first phase of the Sportsbook launch includes Unibet branded kiosks and over-the-counter sports betting. Further development will include an immersive Unibet sports betting lounge, due to launch later this year. Unibet Sportsbook at

Autoliv expands to Vietnam and invests in new airbag cushion plant

(Stockholm, Sweden, April 20, 2023) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announced its plan to build a new state of the art airbag cushion and fabric plant in Vietnam, serving Asia. The investment in the new textile facility is in response to customer demands and is intended to meet expanded future airbag production needs for the growing Asia market.The new facility will be built in Amata City Ha Long Industrial Park, located in the northern part of Vietnam. The facility will showcase Autoliv's manufacturing capabilities

Tomi Alén becomes Partner at CapMan Growth

CapMan Growth press release 20.04.2023 at 9.00 AM EEST Tomi Alén becomes Partner at CapMan Growth Tomi Alén has been appointed as Partner at CapMan Growth as of 5.6.2023. Alén joins CapMan from one of Finland’s top growth companies, RELEX Solutions, where he has for the past two years worked in the role of Senior Vice President Strategy and Corporate Development as part of the company’s extended leadership team. Alén has led the team focusing on the company’s strategy, strategic initiatives, add-on acquisitions, fundraising and investor relations. Through his new role

Viaplay launches on Roku devices in the US, Canada and the UK

· Viewers in North America and the UK can subscribe directly to Viaplay on Roku devices · Roku is the No. 1 TV streaming platform in the US and Canada by hours streamed · Viaplay joined The Roku Channel’s US Premium Subscriptions offering in December Viaplay Group and Roku have agreed a multi-year partnership that makes the Viaplay streaming service available for subscription through Roku devices in the US, Canada and the UK. Viewers in all three countries can now subscribe directly to Viaplay’s full local offerings via Roku, which is the No. 1 TV streaming platform in the US and

MSAB´s annual report for 2022 published

The Swedish version of MSAB's annual report 2022 is now available for download on the company’s website: www.msab.comThe English version of the annual report is expected to be available on MSAB's website on April 22, 2023.This information is information that MSAB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication of the contact person set out below, on April 20, 2023, 08:00 am (CEST).

Ovzon Interim Report January–March 2023

Eventful start to 2023January–March 2023 · Revenue totaled SEK 57 million (100). Adjusted revenue totaled SEK 57 million (97) · Operating profit/loss totaled SEK -23 million (-18). Adjusted operating profit/loss totaled SEK -34 million (18) · Profit/loss after tax totaled SEK -19 million (-12) · Earnings per share totaled SEK -0.37 (-0.23) · Cash flow for the period totaled SEK -72 million (-96) Significant events during the quarter · Announcement regarding the delay of the launch of Ovzon 3, and switch to SpaceX as launch partner · Carried out a directed share

Norse Atlantic ASA: Last day of the subscription period in the subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Arendal, 20 April 2023: Reference is made to the stock exchange announcement by Norse Atlantic ASA (the "Company") on 12 April 2023 regarding launch of the subsequent offering of up to 60,000,000 new shares in the Company at a subscription price of NOK

Olvi Group’s interim report January–March 2023

OLVI PLC                  Interim report 20 April 2023 at 9 am Olvi Group’s interim report January–March 2023 Net sales increased driven by strong demand, but purchase costs remained high · Net sales were EUR 129.5 (103.9) million. The sales volume increased by 7.6%, and net sales grew by 24.6%. · The adjusted operating result was EUR 10.0 (6.4) million, and the operating result was EUR -2.2 (6.4) million. The operating result includes an expense of EUR 12.2 million related to a fine imposed on the subsidiary in Belarus. · A strong balance sheet and a solid financial

Interim Report Safeture AB Q1 2023: Continued improved profitability

· Annual recurring revenue (ARR) growth of +27% to 44,0 MSEK. · Recurring revenue amounts to 10,7 MSEK compared to 8,1 MSEK last year (+31%). · EBIT improvement year-on-year of 2,2 MSEK, reaching -2,5 MSEK . · Bottom-line result at -23% of net sales compared to -57% one year ago. · Quarterly churn at 1,5% · Yearly NRR at 109%Classics First quarter (2023-01-01 to 2023-03-31) • Net revenue amounted to 10 668 (8 152) TSEK (+31%). • Loss after financials amounted to -2 497 (-4 665) TSEK. • Loss per share before dilution amounted to -0,06 (-0,15) SEK. • Loss per

Polygiene Group AB (publ.) publishes Annual Report for 2022

The Annual Report 2022 for Polygiene Group AB (publ.) is now available at the company’s site ir.polygiene.com.  The Annual shareholder meeting will be held Thursday 11 May 2023 at 13.00 at STUDIO, Nordenskiöldsgatan 24, in Malmö.To download the annual report, visit ir.polygiene.com/financial-reportsFor more information contact:Niklas Blomstedt, CFOMobile: +46 (0) 70 663 21 26E-mail: niklas.blomstedt@polygiene.com                     Ulrika Björk, CEOMobile: +46 (0) 70 921 12 75E-mail: ulrika.bjork@polygiene.com This information was submitted for publication, through the

Hansa Biopharma interim report January–March 2023

· Positive reimbursement decision in Spain expands market access to include the five largest European markets · Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed · HNSA-5487: Phase 1 clinical study started in healthy volunteersLund, Sweden, April 20, 2023, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to March 2023. Highlights for the first quarter of 2023 · Total Q1 revenue of SEK 24.2m including SEK 14.3m in product sales

AQ Group AB (publ), interim report January - March, 2023

First quarter, January-March 2023 in brief   · Good start of the year results in growth, improved margin, and cash flow · Net sales increased by 36.8% to SEK 2,253 million (1,646) · Operating profit (EBIT) increased by 72.3% to SEK 194 million (113) · Profit after financial items (EBT) increased by 58.3% to SEK 184 million (116) · Profit margin before tax (EBT %) was 8.2% (7.1) · Cash flow from operating activities amounted to SEK 225 million (44) · Earnings per share after dilution increased by 70.2% to SEK 8.58 (5.04) · Equity ratio was 55% (56) · The Board

Publication of Genetic Analysis’ 2022 Annual Report

(Oslo, April 20, 2023) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the Annual Report for the financial year of 2022. The Annual Report is available as an attached file to this release and on the Company’s website (www.genetic-analysis.com).For further information, please contact:Ronny Hermansen, CEOE-mail: rh@genetic-analysis.com Eilert Aamodt, Chief Financial OfficerE-mail: ea@genetic-analysis.com

There are no items matching the current filter
There are no more items matching the current filter
Back to top